The molecular pathogenesis of chronic lymphocytic leukaemia

Nature Reviews Cancer

Volumn 16, Issue 3, 2016, Pages 145-162

  Fabbri, Giulia ^a   Dalla Favera, Riccardo ^a,b  

^a Columbia University ^*  (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH1 RECEPTOR; PROTEIN; PROTEIN P53; SPLICING FACTOR 3B SUBUNIT 1; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q22-23; CHROMOSOME DELETION 17Q13; CHRONIC LYMPHATIC LEUKEMIA; EPIGENETICS; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; HUMAN; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; REVIEW; RICHTER SYNDROME; TRISOMY 12; TUMOR MICROENVIRONMENT; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84959454423     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.8     Document Type: Review

References (217)

1. Howlader, N., et al. SEER Cancer Statistics Review, 1975-2010. National Cancer Institute Surveillance, Epidemiology and End Results Program [online] http://seer.cancer.gov/csr/1975-2010/(2013
2. Yang, S. M., Li, J. Y., Gale, R. P., & Huang, X. J. The mystery of chronic lymphocytic leukemia (CLL): why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology? Blood Rev. 29, 205-213 (2015
3. Goldin, L. R., Pfeiffer, R. M., Li, X., & Hemminki, K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 104, 1850-1854 (2004
4. Hallek, M., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446-5456 (2008
5. Hallek, M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 90, 446-460 (2015
6. Campo, E., et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117, 5019-5032 (2011
7. Damle, R. N., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840-1847 (1999
8. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848-1854 (1999
9. Strati, P., & Shanafelt, T. D. Monoclonal B cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126, 454-462 (2015
10. Stilgenbauer, S., & Zenz, T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2010, 481-488 (2010
11. Rossi, D., & Gaidano, G. Richter syndrome. Adv. Exp. Med. Biol. 792, 173-191 (2013
12. Tsimberidou, A. M., et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J. Clin. Oncol. 24, 2343-2351 (2006
13. Hallek, M., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376, 1164-1174 (2010
14. Hendriks, R. W., Yuvaraj, S., & Kil, L. P. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat. Rev. Cancer 14, 219-232 (2014
15. Byrd, J. C., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42 (2013
16. Byrd, J. C., et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213-223 (2014
17. Farooqui, M. Z., et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-Arm trial. Lancet Oncol. 16, 169-176 (2015
18. Burger, J. A., et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373, 2425-2437 (2015
19. Furman, R. R., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997-1007 (2014
20. Brown, J. R., et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 123, 3390-3397 (2014
21. O'Brien, S., et al. Update on a Phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients =65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood 124, 1994a (2014
22. O'Brien, S. M., et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood 126, 2686-2694 (2015
23. Byrd, J. C., et al. Acalabrutinib (ACP 196) in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 323-332 (2015
24. Souers, A. J., et al. ABT 199, a potent and selective BCL 2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013
25. No authors listed] ABT 199 shows effectiveness in CLL. Cancer Discov. 4, OF7 (2014
26. Roberts, A. W., et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311-322 (2016
27. Burger, J. A., Ghia, P., Rosenwald, A., & Caligaris-Cappio, F. The microenvironment in mature B cell malignancies: a target for new treatment strategies. Blood 114, 3367-3375 (2009
28. Burger, J. A., & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592-601 (2013
29. Vardi, A., et al. Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. Cancer Res. 74, 4211-4216 (2014
30. Ten Hacken, E., & Burger, J. A. Microenvironment interactions and B cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment. Biochim. Biophys. Acta 1863, 401-413 (2015
31. Kikushige, Y., et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246-259 (2011
32. Damm, F., et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 4, 1088-1101 (2014
33. Genovese, G., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477-2487 (2014
34. Jaiswal, S., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488-2498 (2014
35. Matutes, E., et al. The immunological profile of B cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8, 1640-1645 (1994
36. Caligaris-Cappio, F., Gobbi, M., Bofill, M., & Janossy, G. Infrequent normal B lymphocytes express features of B chronic lymphocytic leukemia. J. Exp. Med. 155, 623-628 (1982
37. Stall, A. M., et al. Ly 1 B cell clones similar to human chronic lymphocytic leukemias routinely develop in older normal mice and young autoimmune (New Zealand Black-related) animals. Proc. Natl Acad. Sci. USA 85, 7312-7316 (1988
38. Caligaris-Cappio, F. B chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 87, 2615-2620 (1996
39. Baumgarth, N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat. Rev. Immunol. 11, 34-46 (2011
40. Klein, U., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194, 1625-1638 (2001
41. Rosenwald, A., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194, 1639-1647 (2001
42. Klein, U., Rajewsky, K., & Kuppers, R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188, 1679-1689 (1998
43. Seifert, M., et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J. Exp. Med. 209, 2183-2198 (2012
44. Kulis, M., et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 44, 1236-1242 (2012
45. Chiorazzi, N., & Ferrarini, M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 117, 1781-1791 (2011
46. Forconi, F., et al. The normal IGHV1 69 derived B cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 115, 71-77 (2010
47. Duhren-von Minden, M., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-Autonomous signalling. Nature 489, 309-312 (2012
48. Bichi, R., et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl Acad. Sci. USA 99, 6955-6960 (2002
49. Speedy, H. E., Sava, G., & Houlston, R. S. Inherited susceptibility to CLL. Adv. Exp. Med. Biol. 792, 293-308 (2013
50. Goldin, L. R., Bjorkholm, M., Kristinsson, S. Y., Turesson, I., & Landgren, O. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica 94, 647-653 (2009
51. Raval, A., et al. Downregulation of death-Associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129, 879-890 (2007
52. Di Bernardo, M. C., et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204-1210 (2008
53. Crowther-Swanepoel, D., et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42, 132-136 (2010
54. Slager, S. L., et al. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood 120, 843-846 (2012
55. Berndt, S. I., et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat. Genet. 45, 868-876 (2013
56. Speedy, H. E., et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 46, 56-60 (2014
57. Shaffer, A. L., Emre, N. C., Romesser, P. B., & Staudt, L. M. IRF4: Immunity. Malignancy! Therapy? Clin. Cancer Res. 15, 2954-2961 (2009
58. De Silva, N. S., Simonetti, G., Heise, N., & Klein, U. The diverse roles of IRF4 in late germinal center B cell differentiation. Immunol. Rev. 247, 73-92 (2012
59. Simonetti, G., et al. IRF4 controls the positioning of mature B cells in the lymphoid microenvironments by regulating NOTCH2 expression and activity. J. Exp. Med. 210, 2887-2902 (2013
60. Shukla, V., Ma, S., Hardy, R. R., Joshi, S. S., & Lu, R. A role for IRF4 in the development of CLL. Blood 122, 2848-2855 (2013
61. Puente, X. S., et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519-524 (2015
62. Dohner, H., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910-1916 (2000
63. Fabbri, G., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208, 1389-1401 (2011
64. Puente, X. S., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011
65. Wang, L., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497-2506 (2011
66. Quesada, V., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47-52 (2012
67. Landau, D. A., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013
68. Landau, D. A., et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525-530 (2015
69. Vogelstein, B., et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
70. Alexandrov, L. B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
71. Ouillette, P., et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 118, 3051-3061 (2011
72. Edelmann, J., et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120, 4783-4794 (2012
73. Papavasiliou, F. N., & Schatz, D. G. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 109 (Suppl.), S35-S44 (2002
74. Xu, Z., Zan, H., Pone, E. J., Mai, T., & Casali, P. Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat. Rev. Immunol. 12, 517-531 (2012
75. Schatz, D. G., & Ji, Y. Recombination centres and the orchestration of V(D)J recombination. Nat. Rev. Immunol. 11, 251-263 (2011
76. Hallek, M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 122, 3723-3734 (2013
77. Rawstron, A. C., et al. Monoclonal B cell lymphocytosis and chronic lymphocytic leukemia. N. Engl. J. Med. 359, 575-583 (2008
78. Klein, U., et al. The DLEU2/miR 15a/16 1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28-40 (2010
79. Migliazza, A., et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B cell chronic lymphocytic leukemia. Blood 97, 2098-2104 (2001
80. Kalachikov, S., et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 42, 369-377 (1997
81. Calin, G. A., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002
82. Palamarchuk, A., et al. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood 115, 3916-3922 (2010
83. Hammarsund, M., et al. Characterization of a novel B CLL candidate gene-DLEU7-located in the 13q14 tumor suppressor locus. FEBS Lett. 556, 75-80 (2004
84. Mertens, D., et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B cell chronic lymphocytic leukemia. Blood 99, 4116-4121 (2002
85. Allegra, D., et al. Defective DROSHA processing contributes to downregulation of MiR 15/-16 in chronic lymphocytic leukemia. Leukemia 28, 99-107 (2013
86. Ouillette, P., et al Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res. 68, 1012-1021 (2008
87. Ouillette, P., et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin. Cancer Res. 17, 6778-6790 (2011
88. Dal Bo, M., et al. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer 50, 633-643 (2011
89. Lia, M., et al. Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood 119, 2981-2990 (2012
90. Cimmino, A., et al. miR 15 and miR 16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944-13949 (2005
91. Del Giudice, I., et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 97, 437-441 (2012
92. Strati, P., et al. Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk. 15, 420-427 (2015
93. Chigrinova, E., et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122, 2673-2682 (2013
94. Fabbri, G., et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J. Exp. Med. 210, 2273-2288 (2013
95. Wierda, W. G., et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 29, 4088-4095 (2011
96. Stankovic, T., & Skowronska, A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk. Lymphoma 55, 1227-1239 (2014
97. Shiloh, Y., & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197-210 (2013
98. Skowronska, A., et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J. Clin. Oncol. 30, 4524-4532 (2012
99. Stankovic, T., et al. Inactivation of ataxia telangiectasia mutated gene in B cell chronic lymphocytic leukaemia. Lancet 353, 26-29 (1999
100. Bullrich, F., et al. ATM mutations in B cell chronic lymphocytic leukemia. Cancer Res. 59, 24-27 (1999
101. Austen, B., et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B CLL. Blood 106, 3175-3182 (2005
102. Austen, B., et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J. Clin. Oncol. 25, 5448-5457 (2007
103. Guarini, A., et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 97, 47-55 (2012
104. Rossi, D., et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-Type chronic lymphocytic leukemia. Blood 119, 2854-2862 (2012
105. Gaidano, G., et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 88, 5413-5417 (1991
106. Wattel, E., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148-3157 (1994
107. Dohner, H., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B cell leukemias. Blood 85, 1580-1589 (1995
108. Ouillette, P., et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin. Cancer Res. 16, 835-847 (2010
109. Zenz, T., et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk. Lymphoma 50, 510-513 (2009
110. Zenz, T., et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, 53 p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114, 2589-2597 (2009
111. Rossi, D., et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117, 3391-3401 (2011
112. Zenz, T., et al Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-Term follow up. Blood 112, 3322-3329 (2008
113. Dicker, F., et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23, 117-124 (2009
114. Rossi, D., et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin. Cancer Res. 15, 995-1004 (2009
115. Malcikova, J., et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 114, 5307-5314 (2009
116. Zenz, T., et al. TP53 mutation and survival in chronic lymphocytic leukemia. J. Clin. Oncol. 28, 4473-4479 (2010
117. Pospisilova, S., et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26, 1458-1461 (2012
118. Rossi, D., et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123, 2139-2147 (2014
119. Malcikova, J., et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia 29, 877-885 (2015
120. Guieze, R., et al. Presence of multiple recurrent mutations revealed by targeted NGS confers poor trial outcome of relapsed/refractory CLL. Blood 126, 2210-2217 (2015
121. Di Ianni, M., et al. A new genetic lesion in B CLL: a NOTCH1 PEST domain mutation. Br. J. Haematol. 146, 689-691 (2009
122. Riches, J. C., et al. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood 123, 4101-4110 (2014
123. Kopan, R., & Ilagan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233 (2009
124. Weng, A. P., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004
125. O'Neil, J., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007
126. Thompson, B. J., et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835 (2007
127. Rosati, E., et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B CLL cells. Blood 113, 856-865 (2009
128. Arruga, F., et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 28, 1060-1070 (2013
129. Gomez-del Arco, P., et al. Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis. Immunity 33, 685-698 (2010
130. Ashworth, T D., et al. Deletion-based mechanisms of Notch1 activation in T ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 116, 5455-5464 (2010
131. Jeannet, R., et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T ALL. Blood 116, 5443-5454 (2010
132. Guy, C. S., et al. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat. Immunol. 14, 262-270 (2013
133. Fortini, M. E., & Bilder, D. Endocytic regulation of Notch signaling. Curr. Opin. Genet. Dev. 19, 323-328 (2009
134. Maura, F., et al. Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. PLoS ONE 10, e0118801 (2015
135. Pozzo, F., et al. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia 30, 182-189 (2015
136. Stilgenbauer, S., et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123, 3247-3254 (2014
137. Cazzola, M., et al. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 121, 260-269 (2013
138. Shin, C., & Manley, J. L. Cell signalling and the control of pre-mRNA splicing. Nat. Rev. Mol. Cell Biol. 5, 727-738 (2004
139. Golas, M M., Sander, B., Will, C. L., Luhrmann, R., & Stark, H. Molecular architecture of the multiprotein splicing factor SF3b. Science 300, 980-984 (2003
140. Te Raa, G. D., et al. The impact of SF3B1 mutations in CLL on the DNA-damage response. Leukemia 29, 1133-1142 (2015
141. Ramsay, A. J., et al. Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia. Leukemia 27, 1600-1603 (2013
142. Mansouri, L., et al. Functional loss of IkappaBepsilon leads to NF ?B deregulation in aggressive chronic lymphocytic leukemia. J. Exp. Med. 212, 833-843 (2015
143. Annunziata, C. M., et al. Frequent engagement of the classical and alternative NF ?B pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007
144. Keats, J. J., et al. Promiscuous mutations activate the noncanonical NF ?B pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007
145. Rossi, D., et al. Alteration of BIRC3 and multiple other NF ?B pathway genes in splenic marginal zone lymphoma. Blood 118, 4930-4934 (2011
146. Rawlings, D. J., Schwartz, M. A., Jackson, S. W., & Meyer-Bahlburg, A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol. 12, 282-294 (2012
147. Ngo, V. N., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011
148. Treon, S. P., et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N. Engl. J. Med. 367, 826-833 (2012
149. Alves, B. N., et al. IkappaBepsilon is a key regulator of B cell expansion by providing negative feedback on cRel and RelA in a stimulus-specific manner. J. Immunol. 192, 3121-3132 (2014
150. Herishanu, Y., et al. The lymph node microenvironment promotes B cell receptor signaling, NF ?B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117, 563-574 (2011
151. Loayza, D., & De Lange, T. POT1 as a terminal transducer of TRF1 telomere length control. Nature 423, 1013-1018 (2003
152. Lei, M., Podell, E. R., & Cech, T. R. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat. Struct. Mol. Biol. 11, 1223-1229 (2004
153. Ramsay, A. J., et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat. Genet. 45, 526-530 (2013
154. Rodriguez, D., et al. Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. Blood 126, 195-202 (2015
155. Clifford, R., et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 123, 1021-1031 (2014
156. Wang, L., et al. Somatic mutation as a mechanism of Wnt/beta-catenin pathway activation in CLL. Blood 124, 1089-1098 (2014
157. O'Brien, P., Morin, P. Jr, Ouellette, R. J., & Robichaud, G. A. The Pax 5 gene: a pluripotent regulator of B cell differentiation and cancer disease. Cancer Res. 71, 7345-7350 (2011
158. Baylin, S. B., & Jones, P. A. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11, 726-734 (2011
159. Kanduri, M., et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 115, 296-305 (2010
160. Cahill, N., et al. 450K array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 27, 150-158 (2013
161. Landau, D. A., et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26, 813-825 (2014
162. Oakes, C. C., et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 4, 348-361 (2014
163. Queiros, A. C., et al. A B cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia 29, 598-605 (2015
164. Nieto, W. G., et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood 114, 33-37 (2009
165. Vardi, A., et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood 121, 4521-4528 (2013
166. Landgren, O., et al. B cell clones as early markers for chronic lymphocytic leukemia. N. Engl. J. Med. 360, 659-667 (2009
167. Lionetti, M., et al. High-Throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br. J. Haematol. 165, 629-639 (2014
168. Ojha, J., et al. Monoclonal B cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia 28, 2395-2398 (2014
169. Ojha, J., et al. Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br. J. Haematol. 169, 445-448 (2015
170. Ojha, J., et al. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood 125, 492-498 (2015
171. Rossi, D., et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119, 521-529 (2012
172. Messina, M., et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood 123, 2378-2388 (2014
173. Greco, M., et al. Analysis of SF3B1 mutations in monoclonal B cell lymphocytosis. Hematol. Oncol. 31, 54-55 (2013
174. Guieze, R., & Wu, C. J. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood 126, 445-453 (2015
175. Rasi, S., et al. Analysis of NOTCH1 mutations in monoclonal B cell lymphocytosis. Haematologica 97, 153-154 (2012
176. Rossi, D., et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118, 6904-6908 (2011
177. Wang, J., et al. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. eLife http://doi.dx.org/10.7554/eLife.02869 (2014
178. Solh, M., et al. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk. Lymphoma 54, 252-254 (2013
179. Weissmann, S., et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 27, 2393-2396 (2013
180. Villamor, N., et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 27, 1100-1106 (2013
181. Wu, Y., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 464, 1052-1057 (2010
182. Monti, S., et al. Integrative analysis reveals an outcome-Associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 22, 359-372 (2012
183. Rossi, D., et al. Stereotyped B cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin. Cancer Res. 15, 4415-4422 (2009
184. Rossi, D., et al. Association between molecular lesions and specific B cell receptor subsets in chronic lymphocytic leukemia. Blood 121, 4902-4905 (2013
185. Gounari, M., et al Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. Blood 125, 3580-3587 (2015
186. Rossi, D., et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121, 1403-1412 (2013
187. Jeromin, S., et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 28, 108-117 (2014
188. Baliakas, P., et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29, 329-336 (2015
189. Oscier, D. G., et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 121, 468-475 (2013
190. Schnaiter, A., et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 122, 1266-1270 (2013
191. Dreger, P., et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow up of the GCLLSG CLL3X trial. Blood 121, 3284-3288 (2013
192. Maddocks, K. J., et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 1, 80-87 (2015
193. Byrd, J. C., et al. Three-year follow up of treatment-naive and previously treated patients with CLL and SLL receiving single-Agent ibrutinib. Blood 125, 2497-2506 (2015
194. Woyach, J. A., et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286-2294 (2014
195. Liu, T. M., et al. Hypermorphic mutation of phospholipase C, ?2 acquired in ibrutinib-resistant CLL confers BTK independency upon B cell receptor activation. Blood 126, 61-68 (2015
196. Cheng, S., et al. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia 29, 895-900 (2015
197. Fama, R., et al. Ibrutinib-naive chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. Blood 124, 3831-3833 (2014
198. Roche-Lestienne, C., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002
199. Hofmann, W. K., et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102, 659-661 (2003
200. Andersson, E. R., & Lendahl, U. Therapeutic modulation of Notch signalling-Are we there yet? Nat. Rev. Drug Discov. 13, 357-378 (2014
201. Kaida, D., et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3, 576-583 (2007
202. Larrayoz, M., et al The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukemia cells through downregulation of Mcl 1. Leukemia 30, 351-360 (2016
203. Rozman, C., & Montserrat, E. Chronic lymphocytic leukemia. N. Engl. J. Med. 333, 1052-1057 (1995
204. Binet, J. L., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206 (1981
205. Rai, K. R., et al. Clinical staging of chronic lymphocytic leukemia. Blood 46, 219-234 (1975
206. Stein, H., et al. Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas. J. Histochem. Cytochem. 28, 746-760 (1980
207. Burger, J. A., Burger, M., & Kipps, T. J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94, 3658-3667 (1999
208. Kurtova, A. V., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114, 4441-4450 (2009
209. Lagneaux, L., Delforge, A., Bron, D., De Bruyn, C., & Stryckmans, P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91, 2387-2396 (1998
210. Lutzny, G., et al. Protein kinase c beta-dependent activation of NF ?B in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 23, 77-92 (2013
211. Burger, J. A. The, C. L. L. Cell Microenvironment. Adv. Exp. Med. Biol. 792, 25-45 (2013
212. Burger, J. A. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2011, 96-103 (2011
213. Pizzolo, G., et al. Immunohistologic study of bone marrow involvement in B chronic lymphocytic leukemia. Blood 62, 1289-1296 (1983
214. Ghia, P., et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur. J. Immunol. 32, 1403-1413 (2002
215. Patten, P. E., et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111, 5173-5181 (2008
216. Os, A., et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep. 4, 566-577 (2013
217. Bagnara, D., et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 117, 5463-5472 (2011